{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:17Z","timestamp":1786997897350,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.vaccine.2018.05.118","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T02:04:35Z","timestamp":1528337075000},"page":"4287-4297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Penton base induces better protective immune responses than fiber and hexon as a subunit vaccine candidate against adenoviruses"],"prefix":"10.1016","volume":"36","author":[{"given":"Kai","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmeng","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinxue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.05.118_b0005","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00705-005-0722-7","article-title":"Molecular typing of human adenoviruses by PCR and sequencing of a partial region of the hexon gene","volume":"151","author":"Lu","year":"2006","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2018.05.118_b0010","first-page":"494","article-title":"Adenovirus. Seminars in respiratory and critical care medicine: \u00a9","author":"Lynch","year":"2011","journal-title":"Thieme Med Publ"},{"key":"10.1016\/j.vaccine.2018.05.118_b0015","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11908-014-0416-y","article-title":"Adenovirus: current epidemiology and emerging approaches to prevention and treatment","volume":"16","author":"Sandkovsky","year":"2014","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.vaccine.2018.05.118_b0020","first-page":"313","article-title":"Adenoviruses associated with acute gastroenteritis in hospitalized and community children up to 5 years old in Rio de Janeiro and Salvador","volume":"56","author":"Pereira Filho","year":"2007","journal-title":"Braz J Microbiol"},{"key":"10.1016\/j.vaccine.2018.05.118_b0025","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/jmv.21701","article-title":"Comprehensive serotyping and epidemiology of human adenovirus isolated from the respiratory tract of Korean children over 17 consecutive years (1991\u20132007)","volume":"82","author":"Lee","year":"2010","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2018.05.118_b0030","article-title":"Fatal community-acquired pneumonia in children caused by re-emergent human adenovirus 7d associated with higher severity of illness and fatality rate","author":"Yu","year":"20166","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2018.05.118_b0035","doi-asserted-by":"crossref","unstructured":"Lynch JP, Kajon AE. Adenovirus: epidemiology, global spread of novel serotypes, and advances in treatment and prevention. Seminars in respiratory and critical care medicine: Thieme Medical Publishers; 2016. p. 586\u2013602.","DOI":"10.1055\/s-0036-1584923"},{"key":"10.1016\/j.vaccine.2018.05.118_b0040","doi-asserted-by":"crossref","unstructured":"Kim Y-J, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Seminars in respiratory and critical care medicine: Copyright\u00a9 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA; 2007. p. 222\u201342.","DOI":"10.1055\/s-2007-976494"},{"key":"10.1016\/j.vaccine.2018.05.118_b0045","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/CMR.00116-13","article-title":"Adenovirus infections in immunocompetent and immunocompromised patients","volume":"27","author":"Lion","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2018.05.118_b0050","doi-asserted-by":"crossref","unstructured":"Ganapathi L, Arnold A, Jones S, Patterson A, Graham D, Harper M, et al. Use of cidofovir in pediatric patients with adenovirus infection. F1000Res 2016;5.","DOI":"10.12688\/f1000research.8374.1"},{"key":"10.1016\/j.vaccine.2018.05.118_b0055","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1016\/j.vaccine.2013.04.035","article-title":"A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits","volume":"31","author":"Kuschner","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.118_b0060","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.vaccine.2012.12.029","article-title":"History of the restoration of adenovirus type 4 and type 7 vaccine, live oral (Adenovirus Vaccine) in the context of the Department of Defense acquisition system","volume":"31","author":"Hoke","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.118_b0065","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1099\/vir.0.000139","article-title":"Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR\/Cas9","volume":"96","author":"Li","year":"2015","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.05.118_b0070","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.virusres.2015.06.002","article-title":"Mapping the epitope of neutralizing monoclonal antibodies against human adenovirus type 3","volume":"208","author":"Tian","year":"2015","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2018.05.118_b0075","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.virol.2012.12.014","article-title":"Characteristics of neutralizing antibodies to adenovirus capsid proteins in human and animal sera","volume":"437","author":"Yu","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.05.118_b0080","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.118_b0085","doi-asserted-by":"crossref","unstructured":"O'brien KL, Liu J, King SL, Sun Y-H, Schmitz JE, Lifton MA, et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009;15:873\u20135.","DOI":"10.1038\/nm.1991"},{"key":"10.1016\/j.vaccine.2018.05.118_b0090","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/JVI.06254-11","article-title":"Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection","volume":"86","author":"Bradley","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.05.118_b0095","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1128\/jvi.62.7.2321-2328.1988","article-title":"Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms","volume":"62","author":"Wohlfart","year":"1988","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.05.118_b0100","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1128\/JVI.72.8.6875-6879.1998","article-title":"Circumvention of immunity to the adenovirus major coat protein hexon","volume":"72","author":"Roy","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.05.118_b0105","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1128\/JVI.77.19.10366-10375.2003","article-title":"Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors","volume":"77","author":"Hong","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.05.118_b0110","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein","volume":"174","author":"Sumida","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.05.118_b0115","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.4049\/jimmunol.1300120","article-title":"CCL19 and CCL28 augment mucosal and systemic immune responses to HIV-1 gp140 by mobilizing responsive immunocytes into secondary lymph nodes and mucosal tissue","volume":"191","author":"Hu","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.05.118_b0120","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1500198","article-title":"Immunization with HSV-2 gB-CCL19 fusion constructs protects mice against lethal vaginal challenge","author":"Yan","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.05.118_b0125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.virol.2011.11.023","article-title":"Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction","volume":"423","author":"Huang","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.05.118_b0130","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1073\/pnas.88.5.1651","article-title":"A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia","volume":"88","author":"Ginsberg","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2018.05.118_b0135","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1128\/AAC.00623-12","article-title":"Bifunctional CD4\u2013DC-SIGN fusion proteins demonstrate enhanced avidity to gp120 and Inhibit HIV-1 Infection and dissemination","volume":"56","author":"Du","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2018.05.118_b0140","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/sj.ijo.0801668","article-title":"Transmissibility of adenovirus-induced adiposity in a chicken model","volume":"25","author":"Dhurandhar","year":"2001","journal-title":"Int J Obes"},{"key":"10.1016\/j.vaccine.2018.05.118_b0145","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1086\/314827","article-title":"Nasal immunization induces haemophilus influenzae\u2014specific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity","volume":"180","author":"Kurono","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.118_b0150","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1286-4579(01)01460-5","article-title":"IgA responses in the intestinal mucosa against pathogenic and non-pathogenic microorganisms","volume":"3","author":"Macpherson","year":"2001","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2018.05.118_b0155","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1086\/522970","article-title":"Abrupt emergence of diverse species B adenoviruses at US military recruit training centers","volume":"196","author":"Metzgar","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.118_b0160","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3201\/eid1605.091633","article-title":"Spread of adenovirus to geographically dispersed military installations, May\u2013October 2007","volume":"16","author":"Trei","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.118_b0165","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/INF.0b013e31819075a6","article-title":"Clinical features, adenovirus types, and local production of inflammatory mediators in adenovirus infections","volume":"28","author":"Moro","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.05.118_b0170","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.virol.2013.08.032","article-title":"Adenovirus serotype 11 causes less long-term intraperitoneal inflammation than serotype 5: Implications for ovarian cancer therapy","volume":"447","author":"Thoma","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.05.118_b0175","doi-asserted-by":"crossref","first-page":"7964","DOI":"10.1128\/JVI.07076-11","article-title":"Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions","volume":"86","author":"Qiu","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.05.118_b0180","doi-asserted-by":"crossref","first-page":"e103058","DOI":"10.1371\/journal.pone.0103058","article-title":"Generation of neutralizing monoclonal antibodies against a conformational epitope of human adenovirus type 7 (HAdv-7) incorporated in capsid encoded in a HAdv-3-based vector","volume":"9","author":"Liu","year":"2014","journal-title":"PLOS One"},{"key":"10.1016\/j.vaccine.2018.05.118_b0185","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.1016\/j.vaccine.2012.10.013","article-title":"A subunit vaccine against hydropericardium syndrome using adenovirus penton capsid protein","volume":"30","author":"Shah","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.118_b0190","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nri3322","article-title":"New concepts in the generation and functions of IgA","volume":"12","author":"Pabst","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2018.05.118_b0195","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrmicro2384","article-title":"The role of secretory antibodies in infection immunity","volume":"8","author":"Strugnell","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2018.05.118_b0200","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1164\/rccm.201312-2158ED","article-title":"Prior exposure to bacteria attenuates viral disease of the respiratory tract: a role for IL-17 and innate immune memory?","volume":"189","author":"Mills","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2018.05.118_b0205","doi-asserted-by":"crossref","unstructured":"Cai CW, Blase JR, Eickhoff CS, Hoft DF. Th17 cells confer both systemic and mucosal protection against Trypanosoma cruzi infection. J Immunol 2017;198:123.1-.1.","DOI":"10.4049\/jimmunol.198.Supp.123.1"},{"key":"10.1016\/j.vaccine.2018.05.118_b0210","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7774\/cevr.2017.6.1.15","article-title":"The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants","volume":"6","author":"Kim","year":"2017","journal-title":"Clin Exp Vaccine Res"},{"key":"10.1016\/j.vaccine.2018.05.118_b0215","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1128\/JVI.76.1.127-135.2002","article-title":"Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response","volume":"76","author":"Molinier-Frenkel","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.05.118_b0220","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","article-title":"Integrins \u03b1v\u03b23 and \u03b1v\u03b25 promote adenovirus internalization but not virus attachment","volume":"73","author":"Wickham","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2018.05.118_b0225","first-page":"351","article-title":"Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States","volume":"11","author":"Nwanegbo","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2018.05.118_b0230","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/08828240050144671","article-title":"Immunoreactive domains and integrin-binding motifs in adenovirus penton base capsomer","volume":"13","author":"Hong","year":"2000","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2018.05.118_b0235","doi-asserted-by":"crossref","first-page":"14429","DOI":"10.1128\/JVI.79.22.14429-14436.2005","article-title":"CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7","volume":"79","author":"Marttila","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.05.118_b0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/viro.2000.0468","article-title":"Cell receptors involved in adenovirus entry","volume":"274","author":"Nemerow","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.05.118_b0245","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2018.05.118_b0250","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1073\/pnas.0711757105","article-title":"Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo","volume":"105","author":"Kalyuzhniy","year":"2008","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:26:19Z","timestamp":1759400779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18307977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":50,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0264410X18307977"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.118","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Penton base induces better protective immune responses than fiber and hexon as a subunit vaccine candidate against adenoviruses","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}